1. NON-SMALL CELL LUNG CANCER: Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical Trials
- Author
-
Oakley, Clayton K., Yellala, Amulya, Tulpule, Sunil, High, Robin, Ganti, Apar Kishor, and Marr, Alissa S.
- Subjects
Patient outcomes ,Product development ,Clinical trials ,Chemotherapy ,Kinase inhibitors -- Product development ,Medical research ,Small cell lung cancer -- Patient outcomes ,Immunotherapy ,Pembrolizumab ,Non-small cell lung cancer -- Patient outcomes ,Antineoplastic agents -- Product development ,Cancer metastasis -- Patient outcomes ,Alectinib ,Medical schools ,Medicine, Experimental ,Metastasis -- Patient outcomes ,Lung cancer, Small cell -- Patient outcomes ,Medical colleges ,Lung cancer, Non-small cell -- Patient outcomes ,Cancer -- Chemotherapy ,Antimitotic agents -- Product development - Abstract
Over the past few years, there has been a significant increase in the eligibility criteria for medical therapy clinical trials enrolling patients with lung cancer, especially for clinical trials focused [...], Introduction: There are limited data available regarding patient outcomes in those who would have been ineligible to receive therapy based on the original clinical trial eligibility criteria. We decided to conduct a retrospective study to evaluate outcomes based on clinical trial eligibility in patients with metastatic non-small cell lung cancer (NSCLC). Methods: A retrospective chart review of all patients with metastatic NSCLC who received first-line systemic therapy at a single academic institution was performed. Each patient's chart was reviewed to determine if they would have qualified for the phase 3 clinical trial that led to the approval of the specific treatment regimen which they received. Data were analyzed to determine if there was a difference in survival time between those who would have been eligible compared with those who were ineligible for the clinical trial of the treatment regimen administered. Results: There were 170 patients with a diagnosis of metastatic NSCLC who received first-line systemic therapy. Of these, 109 received combined chemotherapy, 25 received immunotherapy, and 36 received targeted therapy. There is a statistically significant difference in the restricted mean survival time between the eligible and ineligible groups in those who received combined chemotherapy (19.9 months vs 13.2 months; P = .03), but not in either the immunotherapy group (22.4 months vs 12.9 months; P = .06) or the targeted therapy group (57.7 months vs 39.0 months; P = .14). Conclusion: These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.
- Published
- 2024